Quick Answer
Decoy Therapeutics Inc. reported Stockholders Equity of $5.89 million for the year ending 2025.
- Decoy Therapeutics Inc. showed an increase of +289.6% in Stockholders Equity from 2024 to 2025.
- This data is from Decoy Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2014 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: $74.82 million | Q3 2016: $66.03 million | Q1 2017: $52.23 million | Q2 2017: $44.50 million | Q3 2017: $36.18 million | Q1 2018: -$3.32 million | Q2 2018: -$1.18 million | Q3 2018: -$1.49 million | Q1 2019: $1.73 million | Q2 2019: $732.9 thousand | Q3 2019: $9.74 million | Q1 2020: $18.00 million | Q2 2020: $16.85 million | Q3 2020: $20.61 million | Q1 2021: $48.78 million | Q2 2021: $45.85 million | Q3 2021: $42.65 million | Q1 2022: $33.42 million | Q2 2022: $30.88 million | Q3 2022: $16.61 million | Q1 2023: $5.56 million | Q2 2023: $8.41 million | Q3 2023: $6.08 million | Q1 2024: $3.65 million | Q2 2024: $2.38 million | Q3 2024: $2.92 million | Q1 2025: $61.9 thousand | Q2 2025: -$829.7 thousand | Q3 2025: $4.25 million.
- Historical annual values: Fiscal year 2025: $5.89 million | Fiscal year 2024: $1.51 million | Fiscal year 2023: $5.29 million | Fiscal year 2022: $10.38 million | Fiscal year 2021: $38.72 million | Fiscal year 2020: $22.16 million | Fiscal year 2019: $10.58 million | Fiscal year 2018: -$1.27 million | Fiscal year 2017: -$2.90 million | Fiscal year 2016: $59.32 million | Fiscal year 2015: $92.19 million | Fiscal year 2014: -$6.54 million | Fiscal year 2014: $0.00.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: